Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.04. | Milan: Gains for Philogen | - | Teleborsa | ||
20.02. | Philogen S.p.A.: Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma | 283 | GlobeNewswire (Europe) | FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or... ► Artikel lesen | |
05.12.23 | Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities | 367 | GlobeNewswire (Europe) | SIENA, Italy, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that its new GMP facility located in Rosia Siena, is now GMP certified. The certification was granted... ► Artikel lesen | |
04.12.23 | Philogen S.p.A.; Blue Earth Diagnostics: Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors | 384 | GlobeNewswire (Europe) | Novel ultra-high affinity ligand OncoFAP targets Fibroblast Activation Protein (FAP), associated with a variety of solid tumorsLicensing agreement between Philochem and Blue Earth Diagnostics, one of... ► Artikel lesen | |
16.10.23 | Philogen S.p.A.: Nidlegy Phase III PIVOTAL trial meets the study's primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma | 400 | GlobeNewswire (Europe) | Intratumoral Nidlegy followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone
PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating... ► Artikel lesen | |
01.06.23 | Philogen Announces Clinical Trial Collaboration with MSD | 629 | GlobeNewswire (Europe) | The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and... ► Artikel lesen | |
30.05.23 | Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY in Europe, Australia and New Zealand | 367 | PR Newswire | MUMBAI, India and SIENA, Italy, May 30, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) (together with... ► Artikel lesen | |
30.05.23 | Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY in Europe, Australia and New Zealand | 405 | GlobeNewswire (Europe) | Mumbai, India and Siena, Italy, 30th May
2023 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or... ► Artikel lesen | |
25.05.23 | Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich | 451 | GlobeNewswire (Europe) | Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich
L19TNF (also known as Fibromun) is an... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,160 | -4,98 % | Evotec, HelloFresh, K+S, Lanxess, Varta, Zalando und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
QIAGEN | 37,940 | -1,65 % | Biotech Report: Sektor fester - Evotec und Qiagen können zulegen | (shareribs.com) Frankfurt / New York 22.04.2024 - Biotech-Aktien verzeichneten zum Wochenauftakt im deutschen Handel Kursgewinne. Gesucht waren unter anderem Evotec und Qiagen. Auch an der Wall Street... ► Artikel lesen | |
VERA THERAPEUTICS | 38,690 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
IMMUNOVANT | 27,750 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
KYMERA THERAPEUTICS | 33,350 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
RECURSION PHARMACEUTICALS | 7,840 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
ARCTURUS THERAPEUTICS | 26,170 | -3,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 44,200 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
ARCUTIS BIOTHERAPEUTICS | 8,590 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
DYNE THERAPEUTICS | 23,695 | -5,14 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 13,210 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
KEROS THERAPEUTICS | 54,19 | 0,00 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,600 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
SANA BIOTECHNOLOGY | 8,500 | -0,93 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
ARVINAS | 31,600 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |